Canceropôle Île-de-France

What Canceropôle Île-de-France does

Canceropôle Île-de-France is a French Groupement d'Intérêt Public (GIP) — a public interest group — that has coordinated cancer research across the Île-de-France (Paris) region since 2004, when the network of seven institutions adopted the GIS structure, and acquired its current legal form by government decree on June 7, 2007. It serves the regional academic and clinical cancer research community, which represents approximately 40% of France's national cancer research potential and 42% of national research and care efforts in oncology, including 5 of the 8 INCa-accredited SIRICs and 5 of the 24 national Oncogeriatric Coordination Units (UCOGs). Its member institutions comprise AP-HP, Institut Curie, Gustave Roussy, Institut Pasteur, Sorbonne Université, Université Paris Cité, Université PSL, and Fondation Jean Dausset-CEPH; fourteen additional partners include Inserm, CNRS, CEA, ARS Île-de-France, Ligue contre le Cancer, Fondation ARC, and GEFLUC. Governance is exercised through a Board of Administrators, General Assembly, and Strategic Steering Committee (COPS), led by President Pierre Laurent-Puig, Scientific Director Sergio Roman Roman, and General Secretary Yannick Bono, with a general secretariat of fewer than 4 FTEs.

The organization's core offerings are not commercial products but coordination services and shared resources: ten thematic working groups structuring research in rare cancers, oncogeriatrics, radiotherapy, geocancer, tumor microenvironment, technologies and synergies, philosophy of cancer biology, and pluridisciplinarity in social sciences and humanities; calls for projects under the Emergence and Structuring tracks; MOOCs and bioinformatics tutorials (RNA-seq bulk launched January 12, 2026; Single Cell RNA-seq scheduled October 7, 2026; Epigenetics added in 2026) plus Galaxy and SHRINE tutorials; curated directories of rare cancer researchers, rare cancer lists, and technology platforms; scientific seminars and online multimedia reports since 2011; and administrative management of research projects. Industry-academia bridges are operationalized through the Oncomatch working group with Medicen competitiveness cluster, the Paris Saclay Cancer Cluster (PSCC), and an ARIIS-anchored collaboration charter signed by multiple pharma and biotech partners.

The business model is entirely publicly funded, with no commercial pricing: principal revenue is an INCa grant of €1.125M per year for 2023-2027 (€5.4M for 2023-2025, on top of €30.85M cumulative INCa funding from 2004-2022), supplemented by member-institution contributions and historical Paris Region DIM co-funding (2004-2016). The organization has no revenue-generating products and does not sell services; all training, directories, and working-group outputs are provided free of charge to the Île-de-France research community. As such, financial performance is best understood through grant renewal cycles, scope of thematic activity, and continued accreditation under the French ten-year cancer strategy rather than conventional revenue or ARR metrics.

Name

Canceropôle Île-de-France

Legal name

Groupement d'intérêt public Cancéropôle Île-de-France

Website

https://canceropole-idf.fr

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Canceropôle Île-de-France is a French public interest group (GIP) coordinating cancer research across the Île-de-France region since 2004, serving researchers, clinicians, patients, and institutions through thematic working groups, funding calls, MOOCs, seminars, and shared directories.

Ownership category

akta.pro rank

Product category

Cancer Research Coordination Services

NAICS

Scientific Research and Development Services (5417), Administration of Economic Programs (926)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAJALAB

Health Research Funding Agencies (Public/Quasi-Public)

Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration

Keywords

• Cancer research coordination
• Oncology research networks
• Scientific training programs
• Research funding calls
• Academic collaboration

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Public institutional funding: Cancéropôle Île-de-France operates as a Groupement d'Intérêt Public (GIP) funded primarily by the Institut National du Cancer (INCa) and contributions from its 7 member institutions. INCa funding for the 2023-2027 period is 1.125 million euros per year. Total INCa funding from 2004 to 2022 was 30.85 million euros. The Paris Region also previously funded the Cancéropôle via its DIM program (2004–2016). Member institutions contribute to annual funding.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Canceropôle Île-de-France is a Groupement d'Intérêt Public (GIP) that coordinates and structures cancer research across the Île-de-France region by bringing together 7 major academic and hospital institutions. It runs calls for research projects, thematic working groups, scientific seminars, MOOCs in bioinformatics, and directories of researchers and technology platforms, functioning as a publicly funded regional research-coordination body rather than a commercial provider.

Product overview

Canceropôle Île-de-France is a Public Interest Group (GIP) that coordinates cancer research across the Île-de-France (Paris) region. It operates as a network coordination body rather than a traditional product company. The organization's offerings include: (1) thematic working groups (10 groups covering areas like rare cancers, radiotherapy, tumor microenvironment, geocancer, and technologies & synergies) that structure research networks; (2) training programs including MOOCs on NGS & Cancer (RNAseq bulk and Single Cell RNAseq Analysis); (3) practical resources such as rare cancer lists, researcher directories, platform directories, bioinformatics tutorials, and data integration tutorials; (4) scientific events including seminars and online multimedia reports; and (5) funding programs (Emergence and Structuring calls for projects). The organization also facilitates industry-academia collaboration through the Oncomatch working group with Medicen cluster.

Differentiator

Problem solved

Functional benefit

Products and services

• MOOC NGS & Cancer – RNAseq bulk Open-access continuous self-paced 8-week online training course introducing analysis of bulk RNA-seq data with R Studio using differential gene expression analysis, with an optional one-day face-to-face refresher course. Targeted at researchers in the Île-de-France cancer research community.
• MOOC NGS & Cancer – Single Cell RNAseq Analysis Open-access 8-week self-paced online training course introducing analysis of single-cell RNA-seq data using R Studio, with an optional one-day face-to-face refresher course. Targeted at researchers in the Île-de-France cancer research community.
• MOOC NGS & Cancer – Epigénétique (Epigenetics) Online training course on epigenetics in cancer research, listed on the Cancéropôle Île-de-France training agenda.
• Emergence Call for Projects Funding program enabling development of innovative, risk-taking cancer research projects or those requiring consolidation of preliminary results before submission to national calls. Open to Île-de-France research teams.

Quantifiable outcome

• Île-de-France accounts for ~40% of France's national cancer research output
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Partnerships

23 partnerships are on record, tiered core and minor.

• Medicen (Healthcare Competitiveness Cluster)coreStrategic or Co-development PartnerMedicen is the healthcare competitiveness cluster for Île-de-France, bringing together over 510 players in healthcare innovation. A partnership with Medicen creates a bridge between academia and industry. The Oncomatch working group (coordinated by Medicen and Cancéropôle IDF) fosters academic-industrial collaboration and co-organizes calls for projects (AMI).
• Paris Saclay Cancer Cluster (PSCC)coreStrategic or Co-development PartnerPSCC is the first biocluster accredited in 2023 dedicated to oncology innovation, part of France 2030. It participates in the Oncomatch working group to strengthen links between academia and industry, offering researchers and developers access to expertise, tools, funding, and infrastructure.
• Ligue contre le CancerminorOthersLong-standing partner organization. Representatives are invited to General Assemblies and COPS meetings. Patient representatives participate in working groups and seminars.
• Fondation ARC pour la recherche sur le cancerminorOthersLong-standing partner organization. Representatives invited to General Assemblies and COPS meetings.
• ARIIS (Alliance pour la Recherche et l'Innovation des Industries de Santé)minorStrategic or Co-development PartnerARIIS has signed a collaboration charter with Cancéropôle IDF defining professional and ethical rules for collaboration with industrial partners. Multiple industrial partners have signed the charter including BioAlliance Pharma, Boehringer Ingelheim, Sanofi, Pierre Fabre, Novartis, and others.
• GEFLUC Paris IDF (Groupement des Entreprises Françaises dans la Lutte contre le Cancer)minorOthersAn association of French companies whose missions include funding cancer research, supporting those affected by the disease, and promoting prevention and awareness in the workplace.
• AP-HP (Assistance Publique – Hôpitaux de Paris)coreOthersEurope's leading hospital group, France's leading cancer research organization, accounting for a third of all cancer care in Île-de-France at 8 specialized sites. A member institution of Cancéropôle IDF, contributing to its financing.
• Gustave RoussycoreOthersEurope's leading cancer center, a privately-owned public service organization. Brings together over 2,100 professionals dedicated to care, research, and teaching. A member institution of Cancéropôle IDF.
• Institut CuriecoreOthersNon-profit organization founded in 1909 on Marie Curie's model 'from fundamental research to innovative care.' A member institution of Cancéropôle IDF.
• Institut PasteurcoreOthersWorld-renowned biomedical research center founded in 1887, a private foundation recognized as being in the public interest. Research includes infectious diseases, cancer, genetic diseases, and neurodegenerative disorders. A member institution of Cancéropôle IDF.
• Sorbonne UniversitécoreOthersCreated in 2018 by merger of Université Paris-Sorbonne and Université Pierre et Marie Curie. Plays an active role in many areas of cancer research: genetics, genomics, proteomics, cell biology, immunology, public health. A member institution of Cancéropôle IDF.
• Université Paris CitécoreOthersAwarded 'Initiative d'Excellence' label in 2018. Combines strengths in health, basic and applied sciences, and social sciences. With 20% of Inserm research staff in UMRs, it is a member institution of Cancéropôle IDF.
• Université Paris Science Lettre (PSL)coreOthersComprises 11 institutions including Collège de France, ENS, ESPCI, Institut Curie. Brings together fundamental and applied sciences, engineering, social sciences, humanities, and arts researchers of exceptional quality. A member institution of Cancéropôle IDF.
• Fondation Jean Dausset – CEPHcoreOthersPublic interest foundation with strong scientific impact in genetics, active in cancer, autoimmune diseases, asthma, metabolic diseases, and neurodegenerative disorders. A member institution of Cancéropôle IDF.
• ARS Île-de-France (Agence régionale de santé)coreOthersImplements health policy in the Île-de-France region. Cancéropôle IDF is a member of the ARS Île-de-France Cancer Steering Committee.
• ONCORIF (Organisation Régionale de Lutte contre le Cancer en Île-de-France)minorOthersCreated December 9, 2006, as the specific regional cancer organization for Île-de-France. Co-organizes activities with Cancéropôle IDF on themes of common interest, notably the Elderly Cancer Patients working group.
• CNRS (Centre National de la Recherche Scientifique)minorOthersMajor player in fundamental research worldwide, active in all scientific fields. A research institution partner of Cancéropôle IDF.
• InsermminorOthersBrings together 15,000 researchers, engineers, technicians, and administrative staff to improve health through advancement of knowledge about living organisms and diseases. A research institution partner of Cancéropôle IDF.
• CEA (Commissariat à l'énergie atomique et aux énergies alternatives)minorOthersActive in four fields: low-carbon energies, digital technologies, technologies for the medicine of the future, and defense and security. Contributes to cancer research through medical imaging, structural biology, and large-scale biology. A research institution partner.
• Other Cancéropôles (6 additional regional Cancéropôles)minorOthers6 additional Cancéropôles cover the rest of France: Cancéropôle Est, Grand-Ouest, Grand-Sud-Ouest, Lyon Auvergne Rhône-Alpes, Nord-Ouest, and Provence Alpes Côte d'Azur. Enable sharing of experience and inter-cancéropôle collaborations, including joint MOOC and health democracy initiatives.
• AERIO (Association pour l'Enseignement et la Recherche des Internes en Oncologie)minorOthersAssociation promoting teaching and research in oncology for interns. An exchange partnership has been in place since 2015. Oncology interns are involved in prevention, research, and care development.
• SFjRO (Société Française des Jeunes Radiothérapeutes Oncologues)minorOthersOpen to all interns and young doctors in radiotherapy/oncology. Joint work with SFjRO, SFRO, and RadioTransNet as part of the Radiotherapy working group is setting up structuring actions to promote access to research for young radiotherapists.
• UCOGs (Oncogeriatric Coordination Units) of the Paris RegionminorOthers5 of France's 24 UCOGs are in the Île-de-France region. Cancéropôle IDF's Elderly Cancer Patients working group brings together these 5 UCOGs and the FROG (FRancilian Oncogeriatric Group) to develop interactions and encourage emergence of research projects and training programs.

Scale indicators6 records

Recent moves14 records

Expansion highlights6 records

Direct peers

• Cancéropôle Grand Sud-Ouest: INCa-accredited Cancérople covering southwestern France. Same model of regional cancer research coordination under INCa framework as Cancérople IDF.
• Cancéropôle Est: INCa-accredited Cancérople covering eastern France. Performs the same cancer research coordination, structuring, and funding role as Cancérople IDF in its respective territory.
• Cancéropôle CLARA (Lyon Auvergne Rhône-Alpes): One of the 7 French Cancéroples accredited by INCa. Performs the same regional cancer research coordination function as Cancérople IDF in the Auvergne Rhône-Alpes region, with similar working groups, calls for projects, and training activities.
• Cancéropôle Grand-Ouest: Another INCa-accredited Cancérople covering western France. Directly comparable as a regional cancer research coordination body with similar INCa funding model and member institution structure.
• Cancéropôle PACA: INCa-accredited Cancérople covering the Provence-Alpes-Côte d'Azur region. Functions as the same type of regional cancer research coordination body as Cancérople IDF.
• Cancéropôle Nord-Ouest: INCa-accredited Cancérople covering northwestern France. Direct peer with comparable mandate of structuring cancer research, organizing working groups, and administering funding calls.

Broad incumbents

• Cancer Research UK: The UK's largest cancer research charity and funding body. Comparable as a national-scale cancer research coordination and funding organization, although operating across the entire UK rather than regionally.
• Institut National du Cancer (INCa): The French national cancer agency and principal funder of Cancérople IDF. Operates at national scale with broader scope including SIRIC labeling, the ten-year cancer strategy, and direct national funding programs — INCa is the broader incumbent in the same cancer research coordination space.
• German Cancer Research Center (DKFZ): Germany's national biomedical research institute focused on cancer. Comparable as a national-scale cancer research institution that coordinates research, training, and infrastructure across multiple sites and programs.

Emerging players

• Paris Saclay Cancer Cluster (PSCC): First France 2030 biocluster accredited in 2023, focused specifically on oncology innovation. Participates in Cancérople IDF's Oncomatch working group and represents an emerging, more industry-oriented coordination vehicle in the same oncology research ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/canceropole
• YouTubeyoutube.com/canceropole
• LinkedInlinkedin.com/company/canceropole
• Facebookfacebook.com/canceropoleidf

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canceropôle Île-de-France